SPECTRAL DATA OF REPRESENTATIVE COMPOUNDS
Figure 3a.1: FT-IR spectrum of 4-[(4-acetylphenyl)amino]-2-methylidene-4-oxo
butanoic acid (3a).
Figure 3a.2: 1H NMR spectrum of 4-[(4-acetylphenyl)amino]-2-methylidene-4-oxo
butanoic acid (3a).
Figure 3a.3: LC-MS of 4-[(4-acetylphenyl)amino]-2-methylidene-4-oxobutanoic acid (3a).
Figure 4a.1: FT-IR spectrum of 4-({4-[3-(4-fluorophenyl)prop-2-enoyl] phenyl} amino)-2methylidene-4-oxobutanoic acid (4a).
Figure 4a.2: 1H NMR spectrum of 4-({4-[3-(4-fluorophenyl)prop-2-enoyl] phenyl} amino)-2methylidene-4-oxobutanoic acid (4a).
Figure 4a.3: LC-MS spectrum of 4-({4-[3-(4-fluorophenyl)prop-2-enoyl]phenyl}amino)2-methylidene-4-oxobutanoic acid (4a).
Figure 4g.1: FT-IR spectrum of 4-({3-[3-(4-fluorophenyl)prop-2-enoyl]phenyl}amino)-2methylidene-4-oxobutanoic acid (4g).
Figure 4g.2: 1H NMR spectrum of 4-({3-[3-(4-fluorophenyl)prop-2-enoyl]phenyl} amino)2-methylidene-4-oxobutanoic acid (4g).
Figure 4g.3: LC-MS spectrum of 4-({3-[3-(4-fluorophenyl)prop-2-enoyl]phenyl} amino)-2methylidene-4-oxobutanoic acid (4g).
Figure 5a.1: FT-IR spectrum of N-(4-(5-(4-flurophenyl)-1-phenyl-1H-pyrazol-3-yl)phenyl2-(3-hydroxy-1-phenyl-1H-pyrazol-4-yl)acetamide (5a).
Figure 5a.2: 1H NMR spectrum of N-(4-(5-(4-flurophenyl)-1-phenyl-1H-pyrazol-3-yl)
phenyl-2-(3-hydroxy-1-phenyl-1H-pyrazol-4-yl)acetamide (5a).
Figure 5a.3: 13C NMR spectrum of N-(4-(5-(4-flurophenyl)-1-phenyl-1H-pyrazol-3-yl)
phenyl-2-(3-hydroxy-1-phenyl-1H-pyrazol-4-yl)acetamide (5a).
Figure 5c.1: LC-MS spectrum of N-(4-(5-(4-chlorophenyl)-1-phenyl-1H-pyrazol-3-yl)
phenyl-2-(3-hydroxy-1-phenyl-1H-pyrazol-4-yl)acetamide (5c).
Figure 5e.1: FT-IR spectrum of 2-(3-hydroxy-1-phenyl-1H-pyrazol-4-yl)-N-(4-(5-(4methoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)phenyl)acetamide (5e).
Figure 5e.2: 1H NMR spectrum of 2-(3-hydroxy-1-phenyl-1H-pyrazol-4-yl)-N-(4-(5-(4methoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)phenyl)acetamide (5e).
Figure 5e.3: 13C NMR spectrum of 2-(3-hydroxy-1-phenyl-1H-pyrazol-4-yl)-N-(4-(5-(4methoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)phenyl)acetamide (5e).
Figure
5.5h.1: FT-IR spectrum of N-(3-(5-(4-bromophenyl)-1-phenyl-1H-pyrazol-3yl)phenyl-2-(3-hydroxy-1-phenyl-1H-pyrazol-4-yl)acetamide (5h).
Figure 5h.2: 1H NMR spectrum of N-(3-(5-(4-bromophenyl)-1-phenyl-1H-pyrazol-3-yl)
phenyl-2-(3-hydroxy-1-phenyl-1H-pyrazol-4-yl)acetamide (5h).
Figure 5h.3: 13C NMR spectrum of N-(3-(5-(4-bromophenyl)-1-phenyl-1H-pyrazol-3-yl)
phenyl-2-(3-hydroxy-1-phenyl-1H-pyrazol-4-yl)acetamide (5h).
Figure 5h.4: LC-MS spectrum of N-(3-(5-(4-bromophenyl)-1-phenyl-1H-pyrazol-3-yl)
phenyl-2-(3-hydroxy-1-phenyl-1H-pyrazol-4-yl)acetamide (5h).
Figure 5k.1: FT-IR spectrum of 2-(3-hydroxy-1-phenyl-1H-pyrazol-4-yl)-N-(3-(5-(4methoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)phenyl)acetamide (5k).
Figure 5k.2:
Figure 5k.3:
1
H NMR spectrum of 2-(3-hydroxy-1-phenyl-1H-pyrazol-4-yl)-N-(3-(5-(4methoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)phenyl)acetamide (5k).
13
C NMR spectrum of 2-(3-hydroxy-1-phenyl-1H-pyrazol-4-yl)-N-(3-(5-(4methoxyphenyl)-1-phenyl-1H-pyrazol-3-yl)phenyl)acetamide (5k).